SRX-25

all catalysts(0)

nothing on the calendar yet

News(10)

• Deep dive: Psychedelics back on FDA’s doorstep
  BioSpace takes stock of the psychedelic therapeutics space, which is once again on the cusp of its first FDA approval.
  biospace · 13d ago
• Stakeholders urge FDA to define data, treatment standards as psychedelic drugs near market
  Safety and access were top of mind at Monday’s public hearing exploring the regulation of psychedelic therapies. "The medicine opens the door,” NeuroAlchemy co-founder Michaela Vogt said during the…
  biospace · 14d ago
• Psychedelic therapies ride wave of public favor into FDA hearing
  Heading into an FDA hearing on Monday regarding the future of psychedelic treatments, public comments show wide support for further exploring the therapeutic potential of these compounds—to match r…
  biospace · 15d ago
• Psychedelics on the cusp of market breakthrough as clinical, policy support grow
  While there are several FDA-approved psychiatric medicines on the market, many patients still struggle to achieve lasting symptom relief. Psychedelics could help fill this gap.
  biospace · 1mo ago
• Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
  Eli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst caut…
  biospace · 2mo ago
• ‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics
  After Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum.
  fiercebiotech · 2mo ago
• Lilly makes up to $3.8B psychedelics play in AtaiBeckley takeover
  With the AtaiBeckley acquisition, Eli Lilly is jumping into psychedelics, a drug class that Jefferies analysts say could herald the “biggest change” for the field of psychiatry.
  biospace · 2mo ago
• J&J sees Spravato sales surge as psychedelic competitors loom
  Psychedelics, chiefly Compass Pathways' COMP360, are unlikely to make an immediate dent in the sales of Johnson & Johnson’s depression drug Spravato, H.C. Wainwright’s Patrick Trucchio told BioSpace.
  biospace · 2mo ago
• Another big premium hike on the horizon
  FDA's crackdown on online ketamine retailers, unprecedented health care premium hikes, and more health news from Morning Rounds
  stat · 2mo ago
• Opinion: Trump’s executive order on psychedelics is the right move. But is my field ready for it?
  The psychedelics field is getting what it has long wanted. Now it has to step up.
  stat · 4mo ago